<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 59-year-old female presents to the emergency department after a fall. She reports severe pain in her right hip and an inability to move her right leg. Her past medical history is notable for osteoporosis, rheumatoid arthritis, and has never undergone surgery before. The patient was adopted, and her family history is unknown. She has never smoked and drinks alcohol socially. Her temperature is 98.8F 37.1C, blood pressure is 15090 mmHg, pulse is 110min, and respirations are 22min. Her right leg is shortened, abducted, and externally rotated. A radiograph demonstrates a displaced femoral neck fracture. She is admitted and eventually brought to the operating room to undergo right hip arthroplasty. While undergoing induction anesthesia with inhaled sevoflurane, she develops severe muscle contractions. Her temperature is 103.4F 39.7C. A medication with which of the following mechanisms of action is indicated in the acute management of this patients condition?? A: Ryanodine receptor antagonist, B: GABA agonist, C: Serotonin 1B1D agonist, D: NMDA receptor antagonist, E: Acetylcholine receptor agonist,  <response>: This is a multiple choice question about the acute management of a patient who develops severe muscle contractions and high fever during anesthesia induction prior to hip surgery. Based on the description, the patient is likely experiencing malignant hyperthermia, a rare reaction to inhaled anesthetics like sevoflurane. Malignant hyperthermia is characterized by muscle rigidity, high fever, and metabolic acidosis due to uncontrolled release of calcium from the sarcoplasmic reticulum. The correct medication will prevent further calcium release, allowing muscle relaxation and temperature reduction. A ryanodine receptor antagonist blocks calcium release from the sarcoplasmic reticulum, making it the right choice. GABA agonists, serotonin agonists, NMDA antagonists, and acetylcholine agonists do not address the underlying pathophysiology of malignant hyperthermia.A: Ryanodine receptor antagonist 